6 completed, 2 recruiting, 1 not yet recruiting. 3 Early Phase 1, 2 Not applicable, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow Philip Kern: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RELIANCE: Moringa in Lactation and Early Childhood Moringa Leaf Powder, Carrier - Breast Feeding, Lactation | Not applicable | Not yet recruiting | Philip Kern | 100 | 2026-11-01 | 2026-07-17 |
| The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics Mirabegron 50 MG, Tadalafil 10 MG, Placebo - Pre-diabetes, Obesity | Phase 4 | Recruiting | Philip Kern | 96 | 2021-12-13 | 2026-08-31 |
| Mechanisms for Activation of Beige Adipose Tissue in Humans Placebo, Mirabegron, Mirabegron 50 MG - PreDiabetes | Phase 2 | Recruiting | Philip Kern | 65 | 2020-12-07 | 2026-11-19 |
| Brown Fat Activation Study Mirabegron, Pioglitazone, Mirabegron and Pioglitazone - Obese, Metabolic Syndrome | Early Phase 1 | Completed | Philip Kern | 39 | 2016-09-01 | 2020-02-07 |
| Cold Induced Changes in White Adipose Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy - Obese, Normal Body Weight | Early Phase 1 | Completed | Philip Kern | 26 | 2016-03-01 | 2020-02-07 |
| Blood Lipopolysaccharide (LPS) Rifaximin Study Rifaximin SSD, Placebo - Obese, Insulin Resistance | Phase 2 | Completed | Philip Kern | 12 | 2015-03-01 | 2019-08-21 |
| Metformin to Augment Strength Training Effective Response in Seniors (MASTERS) Progressive Resistance Training, Metformin - Aging | Early Phase 1 | Completed | Philip Kern | 109 | 2015-01-14 | 2019-09-17 |
| Effects of Fish Oils on Inflammation and Insulin Resistance omega-3 fatty acid, placebo - Metabolic Syndrome, Insulin Resistance | Not applicable | Completed | Philip Kern | 33 | 2007-01-01 | 2018-05-16 |
| Mechanisms Underlying Metabolic Syndrome in Obesity Pioglitazone - Metabolic Syndrome, Insulin Resistance | Phase 4 | Completed | Philip Kern | 70 | 2005-04-01 | 2017-06-15 |
Obesity (6) · Metabolic Syndrome (5) · Diabetes Mellitus (3) · Insulin Resistance (3) · Prediabetic State (3) · Inflammation (2) · Breast Feeding (1) · Glucose Intolerance (1) · Hypertrophy (1) · Platelet Glycoprotein IV Deficiency (1)
mirabegron (3) · Pioglitazone (2) · Carrier State (1) · Deuterium Oxide (1) · Fatty Acids, Omega-3 (1) · Metformin (1) · Omacor (1) · Propranolol (1) · Resistance Training (1) · Tadalafil (1)
United States (9)
Charlotte Peterson, Ph.D. (1) · Marcas Bamman, Ph.D (1) · Phililp Kern, MD (1) · Philip A. Kern, M.D. (1)
PMID 30089732, PMID 23328126, PMID 28441958, PMID 30730923, PMID 31557380, PMID 31961829, PMID 33462708, PMID 33571166, PMID 35492586, PMID 35894077
P20RR021954 (1), R01DK071277 (1), R01DK107646 (1), R01DK112282 (1), R01DK124626 (1), R01DK128033 (1), R21DK100258 (1), UL1TR000117 (1)